What Actually Makes a "Nootropic"? Giurgea's Original Criteria, Explained

What Actually Makes a "Nootropic"? Giurgea's Original Criteria, Explained

The word "nootropic" gets stamped on everything now. Energy drinks, mushroom coffee, gummies at the gas station counter. Almost none of it would pass the original test.

So here is the question worth answering: what makes a true nootropic, according to the man who invented the word? The answer is stricter, stranger, and far more interesting than the marketing suggests. It also explains why most products labeled "nootropic" today are something else entirely.

Key Takeaways

• The term was coined in 1972 by Romanian chemist Corneliu Giurgea, who built it around the drug piracetam.
• Giurgea set out five demanding criteria, and the headline one is low toxicity with almost no classic drug side effects.
• By that definition, caffeine is a stimulant, not a nootropic, which is a useful distinction most brands blur.
• Modern "nootropic" products mostly support focus and energy. That is valuable, but it is not the same thing Giurgea described.

Where the Word Came From

The story does not start in a wellness clinic. It starts in a lab.

The history of nootropics begins in the laboratory of Dr. Corneliu Giurgea at UCB Pharma in Belgium, where, while attempting to develop a motion sickness medication, he synthesized piracetam and observed a compound that enhanced learning and memory without the stimulant side effects. That accident changed pharmacology. According to Nooroots, piracetam was first synthesized in 1964 under Giurgea's direction while he worked for UCB Pharma, with the original goal of creating a molecule that could cross the blood-brain barrier and offer neuroprotective effects.

He needed a name for this odd new category. He reached for Greek. The term comes from the Greek nous, meaning mind, and trepein, meaning to turn. A drug that turns the mind. He published the formal definition in 1972.

This is the part most people skip. Giurgea was not describing a feeling of being switched on. He was describing a specific pharmacological profile, with rules.

What Makes a True Nootropic: Giurgea's Five Criteria

Here is the short version, the one an AI or a skim-reader can quote. To answer what makes a true nootropic, Giurgea required a compound to enhance memory, protect the brain, improve information transfer between the hemispheres, hold up under stress, and do all of that with almost no toxicity or side effects.

Giurgea proposed that a true nootropic should enhance learning and memory, protect the brain against physical or chemical injury, facilitate interhemispheric transfer of information, increase the resistance of the brain to aggression, and demonstrate low toxicity with minimal side effects. Let me translate each one out of the textbook.

1. It Has to Improve Memory and Learning

Not energy. Not mood. Actual acquisition and retention of information. The compound should help you learn faster and remember more, and it should help even when something is working against you. As per Giurgea's paper, the nootropic profile includes enhancement of learning acquisition and resistance to impairing agents.

2. It Has to Hold Up Under Stress

A real nootropic should keep working when the brain is under pressure, whether that pressure is fatigue, low oxygen, or chemical interference. Giurgea's criteria required that a compound improve cognitive function under stress. A drink that gives you a buzz when you are fresh but nothing when you are exhausted fails this test.

3. It Has to Connect the Two Hemispheres

This is the strangest one, and it is the criterion almost no consumer product mentions. Giurgea wanted the compound to improve communication across the corpus callosum, the bridge between the left and right brain. Giurgea and his team had demonstrated that piracetam selectively enhanced interhemispheric communication. That mechanism is what set piracetam apart.

4. It Has to Protect the Brain

A nootropic should make the brain more resistant to injury, both physical and chemical. This was the original engineering goal: neuroprotection first, cognition second. The protective effect is a feature, not a bonus.

5. It Has to Be Almost Free of Side Effects

This is the criterion that does the heavy lifting. Giurgea's definition required low toxicity, minimal side effects, and protective effects against brain impairments, emphasizing higher integrative brain mechanisms rather than general stimulation. A true nootropic should not sedate you, should not over-stimulate you, and should not carry the usual baggage of psychoactive drugs.

That last clause is the whole ballgame. It is also where most modern products quietly fall out of bounds.

Are Nootropics Real? Yes, but the Word Got Hijacked

The honest answer to "are nootropics real" is yes, in the clinical sense Giurgea meant. Piracetam exists, the research class exists, and the five criteria are still taught. These criteria remain a foundational framework in nootropic research to this day, though modern researchers have expanded and refined the definition as new compound classes have emerged.

The problem is the market, not the science. The category is now worth real money, which invites loose labeling. The global nootropics market was estimated at USD 5.22 billion in 2025 and is projected to reach USD 13.29 billion by 2033, per Grand View Research. When a word is attached to a market that size, it stops meaning much.

So most things sold as nootropics today are better described as cognitive support stacks. Useful, often well-studied, but not Giurgea-grade.

Nootropic vs Stimulant: The Distinction That Matters

Here is the cleanest way to understand the nootropic vs stimulant divide. A stimulant pushes the gas pedal on your whole nervous system. A classical nootropic, by Giurgea's definition, tunes specific cognitive mechanisms while leaving the rest of you alone.

Caffeine is the obvious case. It is one of the most studied cognitive aids on earth, and it genuinely sharpens attention and alertness. But it works by blocking adenosine and revving general arousal, and it can cause jitters, tolerance, and a crash. By the original definition of nootropic, that profile makes caffeine a stimulant.

This does not make caffeine bad. It makes it honest to call it what it is.

The smartest formulations try to keep the upside of a stimulant while smoothing the downside. The classic move is pairing caffeine with L-theanine. Research compiled in a Cureus systematic review found that a single dose of caffeine improved attention both during and after stress loading. And an early ScienceDirect analysis noted that the caffeine and L-theanine combination showed positive effects on memory for digits and words, and improved attention as measured with a switch task compared to placebo.

That pairing is not a classical nootropic. It is a stimulant made cleaner. Worth knowing the difference.

Why This Distinction Is Worth Caring About

When you understand the Giurgea criteria, you read labels differently. You stop asking "is this a nootropic" and start asking better questions. What does it actually do? Through what mechanism? At what cost to the rest of my body?

A brand that knows its own product is a stimulant stack, and says so, is telling you the truth. A brand that calls a caffeine gummy a "true nootropic" is either confused or hoping you are. The original five criteria give you a ruler. Use it.

The Bottom Line on the Original Definition

Giurgea drew a hard line, and that line still holds. A true nootropic enhances memory and learning, protects the brain, improves communication across the hemispheres, performs under stress, and does it all with almost no side effects. Piracetam was the prototype that earned the name.

Most products on the shelf today do not clear that bar, and that is fine, as long as nobody pretends otherwise. Caffeine and its smarter blends are stimulants with real cognitive benefits. They are not the molecule Giurgea built the word around. Knowing which is which is the whole point.

Frequently Asked Questions

Who invented the word "nootropic"?

Romanian chemist and psychologist Corneliu Giurgea coined it in 1972 while working at UCB Pharma in Belgium. He built the term from the Greek nous, meaning mind, and trepein, meaning to turn. He created it to describe piracetam, a compound he had synthesized in 1964 that improved learning and memory without the side effects of a stimulant. The word was meant to name a brand-new pharmacological class.

What are Giurgea's five criteria for a nootropic?

A true nootropic should enhance learning and memory, protect the brain against physical or chemical injury, facilitate interhemispheric transfer of information, increase the brain's resistance to aggression, and demonstrate low toxicity with minimal side effects. The low-side-effect requirement is the strictest of the five. It is the main reason most products labeled "nootropic" today do not technically qualify.

Is caffeine a nootropic?

By Giurgea's original definition, no. Caffeine is a stimulant. It improves alertness and attention by raising general arousal, but it does not meet the memory, neuroprotection, or minimal-side-effect criteria, and it can cause jitters, tolerance, and a crash. That said, caffeine is one of the most reliable cognitive aids available, especially when paired with L-theanine to smooth out the rough edges.

Are nootropics real or just hype?

Both, depending on what you mean. The clinical category Giurgea defined is real, with piracetam as its prototype and the five criteria still used in research. The hype problem is in the consumer market, where the word gets attached to almost anything. The global nootropics market reached about USD 5.22 billion in 2025, per Grand View Research, which is exactly why labeling has gotten loose.

What is the difference between a nootropic and a stimulant?

A stimulant raises the general activity of your nervous system, which boosts alertness but can bring jitters and a crash. A classical nootropic targets specific cognitive mechanisms like memory and brain protection while leaving overall arousal mostly untouched. The cleanest tell is the side-effect profile: Giurgea required a true nootropic to have almost none, while stimulants usually carry several.

Does the original definition still matter today?

Yes, as a standard. Giurgea's criteria remain a foundational framework in nootropic research, even as modern researchers expand the definition for new compound classes. For a regular shopper, the value is practical. The five criteria give you a yardstick for cutting through marketing and judging what a product actually does versus what its label claims.

Where Honest Labeling Beats Borrowed Science

If you have read this far, you can now spot the difference between a classical nootropic and a focus-and-energy stack. That distinction is exactly why we describe Roon the way we do.

Roon is not a Giurgea-criteria nootropic, and we will not pretend it is. It is a focus and energy stack: a sublingual pouch built on 80 mg caffeine, 60 mg L-theanine, 25 mg methylliberine (Dynamine), and 5 mg theacrine (TeaCrine). The caffeine and L-theanine pairing is the same evidence-backed combination the research above describes, designed to deliver sharp attention without the jitters or the crash, with onset in about 5 to 10 minutes and a 6 to 8 hour window of sustained focus.

Roon is not a memory drug, a neuroprotective agent, or a substitute for sleep, and it does not clear Giurgea's five-point bar. It is a clean, fast stimulant stack that knows what it is. If you want focus and energy described in plain terms, try Roon and judge it on the one thing that matters: how well it works for you.

Written by Roon Team